Investors & Media

Corporate Profile

Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing new treatments for GI disorders. We have licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a potassium competitive acid blocker (P-CAB) in late clinical-stage development for the treatment of gastric acid-related disorders. Vonoprazan has the potential to be the first gastric anti-secretory agent from a new class approved in the United States, Europe, or Canada in over 30 years.

We have initiated a Phase 2 trial to evaluate various doses of vonoprazan as an on-demand therapy for patients with nonerosive reflux disease (NERD) and released topline results from two pivotal Phase 3 clinical trials for the treatment of H. pylori infection and the treatment of erosive GERD.

Phathom has assembled a team of seasoned gastrointestinal and pharmaceutical industry experts with deep expertise in developing GI therapeutics, including anti-secretory agents.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

May 25, 2022

FLORHAM PARK, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the U.S. Food and Drug Administration (FDA) has accepted for...

May 24, 2022

Results from an investigational Phase 3 PHALCON-EE trial demonstrating superior healing at week 2 in patients with LA Grade C/D (moderate-to-severe) erosive esophagitis and superior maintenance of healing at week 24 in all patients with vonoprazan versus lansoprazole shared in oral presentation 1...

May 17, 2022

New investigational data evaluating vonoprazan in erosive esophagitis (EE) Research highlights real-world evidence of unmet needs that exists for the treatment of Helicobacter pylori ( H. pylori ) infection Phathom research recognized with multiple “posters of distinction” by American...

Latest Events